FORM D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM D



NOTICE OF SALE OF SECURITIES PURSUANT TO REGULATION D, **SECTION 4(6), AND/OR**


10/20/2/1	0 1
OMB APPR	OVAL _
OMB Number:	3235-0076
Expires:	į
Estimated averag	je burden 🍴
hours per respons	se 16.Ò0

SEC USE ONLY							
Prefix	Serial						
	<u> </u>						
DATE RECEIVED							
	1						

Name of Offering (check if this is an	amendment and name has changed, and indicate change.)	
Filing Under (Check box(es) that apply): Type of Filing: New Filing An	Rule 504 Rule 505 Rule 506 Section 4(6	S) ULOE RECEIVED
1	A. BASIC IDENTIFICATION DATA	⟨ DEC 2 1 2006 ⟩
1. Enter the information requested about	the issuer	140
Name of Issuer (check if this is an an	nendment and name has changed, and indicate change.)	210
Memory Pharmaceuticals Corp.		(Z 1) / /
Address of Executive Offices 100 Philips Parkway, Montvale, New	(Number and Street, City, State, Zip Code) Jersey 07645	201.802.7100
Address of Principal Business Operations (if different from Executive Offices)	(Number and Street, City, State, Zip Code)	Telephone Number (Including Area Code)
Brief Description of Business	,	
Drug Discovery and Development		PROCESSED
Type of Business Organization corporation business trust	limited partnership, already formed other limited partnership, to be formed	(please specify): JAN 0 9 2007
Actual or Estimated Date of Incorporation of Jurisdiction of Incorporation or Organization	Month Year or Organization: 0 3 917 Actual Eson: (Enter two-letter U.S. Postal Service abbreviation for Sta	timated THOMSON FINANCIAL
77d(6).	ing of securities in reliance on an exemption under Regulation I i ater than 15 days after the first sale of securities in the offerin	į.
and Exchange Commission (SEC) on the ea	arlier of the date it is received by the SEC at the address given by United States registered or certified mail to that address.	below or, if received at that address after the date o
Where To File: U.S. Securities and Exchar	nge Commission, 450 Fifth Street, N.W., Washington, D.C.	20549.
Copies Required: Five (5) copies of this no photocopies of the manually signed copy or	otice must be filed with the SEC, one of which must be manuar bear typed or printed signatures.	ally signed. Any copies not manually signed must b
Information Required: A new filing must of thereto, the information requested in Part C, not be filed with the SEC.	contain all information requested. Amendments need only re , and any material changes from the information previously sup	port the name of the issuer and offering, any change oplied in Parts A and B. Part E and the Appendix nee
Filing Fee: There is no federal filing fee.		
ULOE and that have adopted this form. It are to be, or have been made. If a state re	ice on the Uniform Limited Offering Exemption (ULOE) for ssuers relying on ULOE must file a separate notice with the equires the payment of a fee as a precondition to the claim filed in the appropriate states in accordance with state law	e Securities Administrator in each state where sale for the exemption, a fee in the proper amount sha
· · · · · · · · · · · · · · · · · · ·	ATTENTION	exemption. Conversely, failure to file the

SEC 1972 (6-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.



A. BASIC IDENTIFICATION DATA	28 - E
2. Enter the information requested for the following:	
• Each promoter of the issuer, if the issuer has been organized within the past five years;	!
• Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity se	curities of the issuer.
• Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers	and
Each general and managing partner of partnership issuers.	l I
	
Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General and Managing I	
Full Name (Last name first, if individual) Scullion, Tony	
Business or Residence Address (Number and Street, City, State, Zip Code) 100 Philips Parkway, Montvale, NJ 07645	ļ (
Check Box(es) that Apply Promoter Beneficial Owner Executive Officer Director General and Managing	
Full Name (Last name first, if individual)	
Sulat, James	į
Business or Residence Address (Number and Street, City, State, Zip Code)	Γ •
100 Philips Parkway, Montvale, NJ 07645	į
Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General and	/or
Managing 1	Partner
Full Name (Last name first, if individual)	
Lowe, David	
Business or Residence Address (Number and Street, City, State, Zip Code)	
100 Philips Parkway, Montvale, NJ 07645	1
	/or
Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General and Managing	,
Full Name (Last name first, if individual)	1
Smith, Michael	1
Business or Residence Address (Number and Street, City, State, Zip Code) 100 Philips Parkway, Montvale, NJ 07645	
Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General and Managing	
Full Name (Last name first, if individual) Donabauer, Joseph	
Business or Residence Address (Number and Street, City, State, Zip Code) 100 Philips Parkway, Montvale, NJ 07645	
Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General and Managing	,
Full Name (Last name first, if individual) Lalani, Jzaneen	
Business or Residence Address (Number and Street, City, State, Zip Code) 100 Philips Parkway, Montvale, NJ 07645	
Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General and Managing	i i
Full Name (Last name first, if individual)	
Fleming, Jonathan	1
Business or Residence Address (Number and Street, City, State, Zip Code)	t t
100 Philips Parkway, Montvale, NJ 07645	ļ
(Use blank sheet, or copy and use additional copies of this sheet, as necessary)	i

A BASIC IDENTIFICATION DATA	
2. Enter the information requested for the following:	j j
• Each promoter of the issuer, if the issuer has been organized within the past five years;	+
• Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity security	ies of the issuer
• Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and	j
Each general and managing partner of partnership issuers.	
	1
Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General and/or Managing Parts	ier
Full Name (Last name first, if individual) Evnin, Anthony	
Business or Residence Address (Number and Street, City, State, Zip Code) 100 Philips Parkway, Montvale, NJ 07645	
Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General and/or Managing Parts	ıer
Full Name (Last name first, if individual) Gilbert, Walter	
Business or Residence Address (Number and Street, City, State, Zip Code) 100 Philips Parkway, Montvale, NJ 07645	
Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General and/or Managing Parts	ner
Full Name (Last name first, if individual) Kriebel, Robert	İ
Business or Residence Address (Number and Street, City, State, Zip Code)	
100 Philips Parkway, Montvale, NJ 07645	1
Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General and/or Managing Parts	ner
Full Name (Last name first, if individual) Kailian, Vaughn	
Business or Residence Address (Number and Street, City, State, Zip Code) 100 Philips Parkway, Montvale, NJ 07645	
Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General and/or Managing Parts	ner
Full Name (Last name first, if individual) Meyers, Michael	
Business or Residence Address (Number and Street, City, State, Zip Code) 100 Philip's Parkway, Montvale, NJ 07645	
Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General and/or Managing Parts	ner
Full Name (Last name first, if individual) Young, Peter	
Business or Residence Address (Number and Street, City, State, Zip Code) 100 Philips Parkway, Montvale, NJ 07645	
Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General and/or Managing Part	ner !
Full Name (Last name first, if individual) Murray, Stephen R.	1
Business or Residence Address (Number and Street, City, State, Zip Code) 100 Philips Parkway, Montvale, NJ 07645	
(Use blank sheet or copy and use additional copies of this sheet as necessary)	1.

·		9			B. II	NFORMATI	ION ABOU	T OFFERI	NG				ĺ
1.			or does t			II, to non-a						Yes	No 🗷
2.	What is	the minim	์ um investก			pted from a		_				s_1,0	00.00
			·!									Yes	No
3.						le unit?						×	
4.	Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission or similar remuneration for solicitation of purchasers in connection with sales of securities in the offering. If a person to be listed is an associated person or agent of a broker or dealer registered with the SEC and/or with a state or states, list the name of the broker or dealer. If more than five (5) persons to be listed are associated persons of such a broker or dealer, you may set forth the information for that broker or dealer only.												
		Last name : ierica Secu											
			1		Street Ci	ty, State, Z	in Code)	<u> </u>	· · · · · · · · ·				
		Street, 40	,			-	np Code)						1
		sociated Br											<u>-</u>
	:		<u>{</u>										(
Stat	tes in Wh	ich Person	Listed Ha	s Solicited	or Intends	to Solicit I	Purchasers						-
	(Check	"All States	" or check	inđividual	States)							☐ VI	l States
	AL. IL MT RI	AK IN NE SC	AZ IA NV SD	AR KS NH TN	KY NJ TX	CO LA NM UT	ME NY VT	MD NC VA	DC MA ND WA	FL MI OH WV	GA MN OK WI	HI MS OR WY	MO PA PR
		Last name		ividual)		ļ.							
		Residence on Avenue				ity, State, 2	Zip Code)		·				1
		sociated Br			<u> </u>								
Stat		i				to Solicit 1							
	(Check	"All States	" or check	individual	States)				***************************************			☐ AI	Il States
	AL IL MT RI	AK IN NE SC	IA NV SD	AR KS NH TN	CA KY NJ TX	LA NM UT	CT ME NY VT	DE MD NC VA	MA ND WA	FL MI OH WV	GA MN OK WI	MS OR WY	MO PA PR
	-	Last name : Markets Co		ividual)		!					<u> </u>		
		Residence in Avenue,				ity, State, 2	Zip Code)		· -				1
		sociated Br			, 191 100		-						
_						····							<u> </u>
Stat	2					to Solicit 1							11 Canada
	(Cneck	"All States	or check	individuai	States)		***************************************			***************************************	**************************	∐ A!	Il States
	IL MT RI	AK IN NE SC	IA NV SD	KS NH TN	KY KY TX	CO LA NM UT	ME NY VT	MD NC VA	DC MA ND WA	MI OH WV	GA MN OK WI	MS OR WY	ID MO PA PR

I.	sold. Enter "0" i	the offering price of securities included in this offering and the total amount already of the answer is "none" or "zero." If the transaction is an exchange offering, check dicate in the columns below the amounts of the securities offered for exchange and add.	Aggregate	Amount Already
	Type of Secu	rity (Offering Price	Sold
	Debt	<u> </u>		s
	Equity		32,219,999.53	\$ 32,219,999.53
		Common Preferred		1.
	Convertible S	Securities (including warrants)\$_	9,387,195.86	9,387,195.86
		nterests\$_		s
	Other (Specif	fy		\$
		\$ \$		
		Answer also in Appendix, Column 3, if filing under ULOE.		1
2.	offering and the a	of accredited and non-accredited investors who have purchased securities in this ggregate dollar amounts of their purchases. For offerings under Rule 504, indicate ersons who have purchased securities and the aggregate dollar amount of their total lines. Enter "0" if answer is "none" or "zero."		Aggregate
			Number Investors	Dollar Amount of Purchases
	Accredited I	nvestors	3	\$_30,107,976.2
	Non-accredi	ted Investors		s
	Total	(for filings under Rule 504 only)		s!
3.	sold by the issuer	Answer also in Appendix, Column 4, if filing under ULOE. an offering under Rule 504 or 505, enter the information requested for all securities, to date, in offerings of the types indicated, in the twelve (12) months prior to the		
	first sale of secur	ities in this offering. Classify securities by type listed in Part C — Question 1.	Type of	Dollar Amount
	Type of Offe		Security	Sold
	Rule 505	:		\$ <u> </u>
		\		s
	Rule 504	. 1		s _
	Total			\$ 0.00
4	securities in this The information r not known, furni	attement of all expenses in connection with the issuance and distribution of the offering. Exclude amounts relating solely to organization expenses of the insurer, may be given as subject to future contingencies. If the amount of an expenditure is shan estimate and check the box to the left of the estimate.		
	Transfer Age	ent's Fees		\$
	Printing and	Engraving Costs		\$
	Legat Fees.			\$ 75,000.00
	Accounting	Fees	2	\$ 9,000.00
	Engineering	Fces		s
	Sales Comm	issions (specify finders' fees separately)		\$
	,	ses (identify)	_	\$
		- 1		\$ 84,000.00

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

			AND USE OF PROCEEDS	
	and total expenses furnished in response to	regate offering price given in response to Part 0 o Part C — Question 4.a. This difference is the	"adjusted gross	\$41,523,195.39
5.	each of the purposes shown. If the amo	ed gross proceed to the issuer used or propose bunt for any purpose is not known, furnish a The total of the payments listed must equal the nse to Part C — Question 4.b above.	an estimate and	
)	Payments to Officers, Directors, & Affiliates	Others
		1		_ [] s
	Purchase, rental or leasing and installat	ion of machinery		_ 🗆 S!
		gs and facilities		
	i			- D\$i
	offering that may be used in exchange f	ing the value of securities involved in this for the assets or securities of another		,
			S	_ 🗆 \$
	Repayment of indebtedness			\$
	Working capital		s	\$41,523,195.
	Other (specify):	:	🗆 \$	_ [] \$i
		· · · · · · · · · · · · · · · · · · ·	🗀 \$	_ 🗆 \$!
	l l			1
	ŧ	'		- -
	Total Payments Listed (column totals ac	dded)		41,523,195.39
		D FÉDERAL SIGNATURE		
١.	or in the first term of the f	D. PEDEKAL SIGNATURE	Balain take at the second of t	
The	issuer has duly caused this notice to be sig	gned by the undersigned duly authorized person	on. If this notice is filed under R	ule 505, the following
sigr	issuer has duly caused this notice to be signature constitutes an undertaking by the is		on. If this notice is filed under R change Commission, upon writ	tule 505, the following ten request of its staff,
sigr the	issuer has duly caused this notice to be signature constitutes an undertaking by the is	gned by the undersigned duly authorized personant to furnish to the U.S. Securities and Ex	on. If this notice is filed under R change Commission, upon writ traph (b)(2) of Rule 502.	ten request of its staff,
sigr the Issu	issuer has duly caused this notice to be signature constitutes an undertaking by the is information furnished by the issuer to an	gned by the undersigned duly authorized personant to furnish to the U.S. Securities and Expression pursuant to parag	on. If this notice is filed under R change Commission, upon writ traph (b)(2) of Rule 502.	ten request of its staff,
sigr the Issu Me	issuer has duly caused this notice to be signature constitutes an undertaking by the is information furnished by the issuer to an ter (Print or Type)	gned by the undersigned duly authorized personant to furnish to the U.S. Securities and Expression pursuant to parag	on. If this notice is filed under R change Commission, upon writ traph (b)(2) of Rule 502.	tule 505, the following ten request of its staff,
sigr the Issu Me Nar	issuer has duly caused this notice to be signature constitutes an undertaking by the is information furnished by the issuer to an ter (Print or Type)	gned by the undersigned duly authorized personant to furnish to the U.S. Securities and Expression pursuant to parage Signature	on. If this notice is filed under R change Commission, upon writ traph (b)(2) of Rule 502.	ten request of its staff,
sigr the Issu Me Nar	issuer has duly caused this notice to be signature constitutes an undertaking by the is information furnished by the issuer to an er (Print or Type) emory Pharmaceuticals Corp. ne of Signer (Print or Type)	gned by the undersigned duly authorized personant to furnish to the U.S. Securities and Expression pursuant to parage Signature Title of Signer (Print or Type)	on. If this notice is filed under R change Commission, upon writ traph (b)(2) of Rule 502.	ten request of its staff,
sigr the Issu Me Nar	issuer has duly caused this notice to be signature constitutes an undertaking by the is information furnished by the issuer to an er (Print or Type) emory Pharmaceuticals Corp. ne of Signer (Print or Type)	gned by the undersigned duly authorized personant to furnish to the U.S. Securities and Expression pursuant to parage Signature Title of Signer (Print or Type)	on. If this notice is filed under R change Commission, upon writ traph (b)(2) of Rule 502.	ten request of its staff,
sigr the Issu Me Nar	issuer has duly caused this notice to be signature constitutes an undertaking by the is information furnished by the issuer to an er (Print or Type) emory Pharmaceuticals Corp. ne of Signer (Print or Type)	gned by the undersigned duly authorized personant to furnish to the U.S. Securities and Expression pursuant to parage Signature Title of Signer (Print or Type)	on. If this notice is filed under R change Commission, upon writ traph (b)(2) of Rule 502.	ten request of its staff,
sigr the Issu Me Nar	issuer has duly caused this notice to be signature constitutes an undertaking by the is information furnished by the issuer to an er (Print or Type) emory Pharmaceuticals Corp. ne of Signer (Print or Type)	gned by the undersigned duly authorized personant to furnish to the U.S. Securities and Expression pursuant to parage Signature Title of Signer (Print or Type)	on. If this notice is filed under R change Commission, upon writ traph (b)(2) of Rule 502.	ten request of its staff,
sigr the Issu Me Nar	issuer has duly caused this notice to be signature constitutes an undertaking by the is information furnished by the issuer to an er (Print or Type) emory Pharmaceuticals Corp. ne of Signer (Print or Type)	gned by the undersigned duly authorized personant to furnish to the U.S. Securities and Expression pursuant to parage Signature Title of Signer (Print or Type)	on. If this notice is filed under R change Commission, upon writ traph (b)(2) of Rule 502.	ten request of its staff,
sigr the Issu Me Nar	issuer has duly caused this notice to be signature constitutes an undertaking by the is information furnished by the issuer to an er (Print or Type) emory Pharmaceuticals Corp. ne of Signer (Print or Type)	gned by the undersigned duly authorized personant to furnish to the U.S. Securities and Expression pursuant to parage Signature Title of Signer (Print or Type)	on. If this notice is filed under R change Commission, upon writ traph (b)(2) of Rule 502.	ten request of its staff,
sigr the Issu Me Nar	issuer has duly caused this notice to be signature constitutes an undertaking by the is information furnished by the issuer to an er (Print or Type) emory Pharmaceuticals Corp. ne of Signer (Print or Type)	gned by the undersigned duly authorized personant to furnish to the U.S. Securities and Expression pursuant to parage Signature Title of Signer (Print or Type)	on. If this notice is filed under R change Commission, upon writ traph (b)(2) of Rule 502.	ten request of its staff,
Issu Me Nar	issuer has duly caused this notice to be signature constitutes an undertaking by the is information furnished by the issuer to an er (Print or Type) emory Pharmaceuticals Corp. ne of Signer (Print or Type)	gned by the undersigned duly authorized personant to furnish to the U.S. Securities and Expression pursuant to parage Signature Title of Signer (Print or Type)	on. If this notice is filed under R change Commission, upon writ traph (b)(2) of Rule 502.	ten request of its staff,
Issu Me Nar	issuer has duly caused this notice to be signature constitutes an undertaking by the is information furnished by the issuer to an er (Print or Type) emory Pharmaceuticals Corp. ne of Signer (Print or Type)	gned by the undersigned duly authorized personant to furnish to the U.S. Securities and Expression pursuant to parage Signature Title of Signer (Print or Type)	on. If this notice is filed under R change Commission, upon writ traph (b)(2) of Rule 502.	ten request of its staff,
Issu Me Nar	issuer has duly caused this notice to be signature constitutes an undertaking by the is information furnished by the issuer to an er (Print or Type) emory Pharmaceuticals Corp. ne of Signer (Print or Type)	gned by the undersigned duly authorized personant to furnish to the U.S. Securities and Expression pursuant to parage Signature Title of Signer (Print or Type)	on. If this notice is filed under R change Commission, upon writ traph (b)(2) of Rule 502.	ten request of its staff,

		E STATE SIGNATURE			
1.	Is any party described in provisions of such rule?	17 CFR 230.262 presently subject to any of the disqualifi	cation	Yes	No X
	į,	See Appendix, Column 5, for state respon	se.		į
2.		reby undertakes to furnish to any state administrator of any ich times as required by state law.	state in which this notice is fi	led a no	tice on Form
3.	The undersigned issuer hissuer to offerees.	reby undertakes to furnish to the state administrators, up	on written request, informat	ion furn	ished by the
4.	limited Offering Exempti	presents that the issuer is familiar with the conditions that in (ULOE) of the state in which this notice is filed and und burden of establishing that these conditions have been sa	derstands that the issuer claim		
The issu	uer has read this notification	and knows the contents to be true and has duly caused this n	otice to be signed on its beha	lf by the	undersigned
	thorized person.				Ī
-	(Print or Type) y Pharmaceuticals Corp.	Signature	Dae	20.	10006
Name (Print or Type)	Title (Print or Type)	V_V_V_V	trust.	744
Jzanee	en Lalani	Vila President Legal Affairs			i
	i ^a		• • • • • • • • • • • • • • • • • • • •		;

Instruction:

Print the name and title of the signing representative under his signature for the state portion of this form. One copy of every notice on Form D must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

ed C				A)	PPENDIX		Charles Company	*	
1	Intend to non-a investor	I to sell ccredited s in State -Item 1)	Type of security and aggregate offering price offered in state (Part C-Item 1)	;	amount pu	investor and rchased in State C-Item 2)		under Sta (if yes, explana	ification ate ULOE attach ation of granted)
State	Yes	No		Number of Accredited Investors	Amount	Number of Non-Accredited Investors	Amount	Yes	No
AL				i		,			
AK				1			:		
AZ									
AR	. di								
CA			C/S & Warrants	1	\$45,144.40				×
СО									
CT			C/S & Warrants	1	\$99,999.66				×
DE			C/S & Warrants	7	\$28,842,8	32.49			×
DC									
FL				į					
GA		İ							
ні				,	-				
ID				r					
IL				1					
IN				'					
ĪΑ						- :			
KS				l ,					
KY				,		,	····		
LA				4					
ME	May be a separation of the sep	1							
MD				:					
MA									
MI	:			:					
MN									
MS							 -		

APPENDIX 2 3 4 Disqualification under State ULOE Type of security · Intend to sell and aggregate (if yes, attach: to non-accredited offering price Type of investor and explanation of offered in state amount purchased in State waiver granted) investors in State (Part C-Item 1) (Part C-Item 2) (Part E-Item 1) (Part B-Item 1) Number of Number of Accredited Non-Accredited No No Investors State Yes Amount **Investors** Amount Yes МО MT NE NVNH NJ NM C/S & Warrants \$1,119,999.69 NY NC ND ОН OK OR PA RI SC SD TN TX UT VŢ ٧A WA wv WI

	. 8			APP	ENDIX					
1	,	2	3 Type of security		4			Disqualification under State ULOE		
	to non-a	d to sell accredited is in State 3-Item 1)	 and aggregate offering price offered in state (Part C-Item 1) 		Type of investor and amount purchased in State (Part C-Item 2)			(if yes, attach explanation of waiver granted) (Part E-Item 1)		
State	Yes	No		Number of Accredited Investors	Amount	Number of Non-Accredited Investors	Amount	Yes	No	
WY										
PR										